188 participants
A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-08-03
- Start Date:
- 2023-03-06
- Completion:
- 2029-11-22
Conditions
- Stage II-IIIB Non-small Cell Lung Carcinoma
Interventions
- DRUG
No Results Yet